ArticleFrontiers in medicine2026
The gut microbiota and plasma metabolites on functional dyspepsia: a study integrating Mendelian randomization and experimental validation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This two-sample Mendelian randomization (MR) investigation aimed to explore how gut microbiota influences functional dyspepsia (FD) via plasma metabolites. The results were then confirmed Methods: A GWAS of 7,738 people was used to generate genetic instruments for 412 gut microbiota characteristics. The NHGRI-EBI GWAS Catalog listed 1,400 plasma metabolites, and the FinnGen biobank provided FD summary statistics. Using the inverse-variance weighted (IVW) approach, potential causal links between gut microbiota and plasma metabolites in FD were assessed. To make sure it was resilient, pleiotropy and heterogeneity evaluations were performed. For experimental validation, the combination of 0.2% iodoacetamide gavage combined with tail-clamp stress was used to create an FD rat model. Fecal and plasma samples from the rats were analyzed to verify the MR findings. Results: Three gut microbiota taxa and two microbial metabolic pathways were identified to be associated with FD. The superpathway of pyridoxal 5'-phosphate biosynthesis and salvage (OR: 0.89; 95% CI: 0.81-0.97; Conclusion: Three gut microbiota taxa and two pathways reflecting microbial composition and activity were associated with FD and linked to alterations in 81 metabolites or metabolite ratios. This study identifies a correlation between altered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.